Eupraxia Pharma Announces Second Set Of 52-Week Follow Up Data From Ongoing Phase 1b/2a RESOLVE Trial Evaluating Single Administration EP-104GI For EoE Treatment

Author: Benzinga Newsdesk | November 13, 2025 05:04pm

• The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far.
• In Cohort 6, a durable clinical symptom response was observed 52 weeks after a single administration of EP-104GI.
• All 3 patients in Cohort 6 maintained a clinical benefit and 2 out of 3 patients remain in clinical remission 52 weeks after treatment of EoE with EP-104GI.
• In combination with patients from Cohort 5, at 52 weeks, 4 out of 6 patients remain in clinical remission.
• At week 36, 67% of all patients in the trial that were measured at 36 weeks, were in clinical remission (Cohorts 5-7, n=9).
   
• Over 200 patient-months of follow-up across all cohorts, with no Serious Adverse Events ("SAEs") and no oral or gastrointestinal candidiasis reported.

VICTORIA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis ("EoE").

Posted In: EPRX TSX:EPRX